Efficacy of treatment for acneiform eruptions related to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC): A protocol of systematic review and network meta-analysis.

Abstract

BACKGROUND:

Acneiform eruptions from epidermal growth factor receptor tyrosine kinase inhibitors is a frequent adverse event in non-small cell lung cancer patients but the efficacy of its treatment including antibiotics, corticosteroid, sunscreen is still poorly understood.

METHODS:

Eight electronic databases (PubMed, EMBASE, ClinicalTrials.gov, etc) will be searched from inception to April 2020. Risk of bias of randomized controlled trials will be assessed in terms of the Risk of Bias 2 (RoB 2) tool. Eligible randomized controlled trials will be enrolled for a Bayesian network meta-analysis using R software.

RESULTS:

This study is still ongoing and the results will be submitted and published in a peer-reviewed scientific journal.

CONCLUSION:

We hope the results of this study will provide reliable evidence for the management of acneiform due to epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.

ETHICS AND DISSEMINATION:

Ethical approval is not applicable for this study is based on published trials.

PROTOCOL REGISTRATION NUMBER:

CRD42020206724.

• Authors: Canfeng He, Ruiting Lin, Jing Zhang, Lingling Sun, Jietao Lin, Lizhu Lin
• Journal: Medicine (Medicine (Baltimore)) Vol. 100 Issue 1 Pg. e23875 (Jan 08 2021) ISSN: 1536-5964 [Electronic] United States
• PMID: 33429746 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Chemical References

• EGFR protein, human
• ErbB Receptors

Topics

• Acneiform Eruptions (drug therapy)
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics)
• Clinical Protocols
• ErbB Receptors (analysis)
• Humans
• Meta-Analysis as Topic
• Systematic Reviews as Topic